Livogiva यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

livogiva

theramex ireland limited - teriparatidi - osteoporoosi - kalsiumin homeostaasi - livogiva is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Lumykras यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Sondelbay यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

sondelbay

accord healthcare s.l.u. - teriparatidi - osteoporoosi - kalsiumin homeostaasi - sondelbay is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Locametz यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - radionuklidien kuvantaminen - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Teriparatide Sun यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

teriparatide sun

sun pharmaceutical industries europe b.v. - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Kauliv यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Herwenda यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

herwenda

sandoz gmbh - trastutsumabi - breast neoplasms; stomach neoplasms - antineoplastiset aineet - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Degarelix Accord यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatiset kasvaimet - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Panapar 500 mg tabletti, kalvopäällysteinen फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

panapar 500 mg tabletti, kalvopäällysteinen

haleon denmark aps - paracetamol - tabletti, kalvopäällysteinen - 500 mg - parasetamoli

Perxine 50 mg/g emulsiovoide फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

perxine 50 mg/g emulsiovoide

infectopharm arzneimittel und consilium gmbh - permethrin - emulsiovoide - 50 mg/g - permetriini